Researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene or 'oncogene,' and how its activities impact pancreatic cancer outcomes. KRAS ...

VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...

Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined, these ...

As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream signaling ...